來寶網Logo

熱門詞:生物顯微鏡 水質分析儀 微波消解 熒光定量PCR 電化學工作站 生物安全柜

現在位置首頁>技術資料首頁>行業動態>公司動態>西門子與Bio-Rad 合作

西門子與Bio-Rad 合作

Siemens2011年12月20日 17:55 點擊:1444


西門子 美國BIO-RAD伯樂



 

Siemens and Bio-Rad Extend Joint Marketing Agreement for IMMULITE and Dimension Systems to Further Optimize Efficiency and Data Reliability

 



The agreement’s extension provides laboratorians with consistent control product and data management tools across the Siemens clinical laboratory portfolio

 

Hercules, Calif., and Tarrytown, N.Y., December 13, 2011 – Today, Siemens Healthcare Diagnostics and Bio-Rad Laboratories, Inc. announced an expansion of a global joint marketing agreement in which Bio-Rad will provide its quality control (QC) products and Unity™ data management solutions for Siemens’ IMMULITE® Immunoassay, Dimension® Integrated Chemistry and Dimension Vista® Intelligent Lab systems. This move extends clinical laboratories’ access to Bio-Rad’s consistent control product and data management tools within the Siemens clinical laboratory systems portfolio which, until today, were only available through Siemens’ ADVIA® Chemistry and ADVIA Centaur® Immunoassay systems.

Through this agreement, laboratories using Bio-Rad controls and Siemens proprietary-labeled controls on Siemens immunoassay and chemistry systems can participate in Bio-Rad’s comprehensive Unity Interlaboratory Program. Bio-Rad’s Unity software products offer varying levels of functionality, ranging from basic Internet-based data submission to advanced real-time QC data management, rules evaluation and analysis.

This joint marketing agreement is the result of a quantitative market research conducted by Siemens in which the company discovered that 80 percent of laboratories ranked improvement of QC data management and the need for multi-analyte controls to perform QC as either extremely important or very important. The research was conducted among nearly 400 hospital and private laboratories in the United States, Japan and five European countries in an effort to better understand their QC control and management needs.

“Siemens recognizes the importance of continually providing its laboratory customers access to advanced QC tools that bring confidence to testing and contribute to improved healthcare outcomes,” said Dave Hickey, CEO, Chemistry, Immunoassay, Automation and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics. “We are pleased to extend our partnership with Bio-Rad, which we believe will help to address the QC management challenges experienced by laboratories by helping them to further streamline inventory management, enhance efficiencies, ensure the reliability of patient results and lead to overall cost savings.”
 

 

“We are pleased to extend our partnership with Siemens Healthcare Diagnostics,” said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. “As a result, customers will have another portal to access Bio Rad’s comprehensive line of multi-analyte quality controls and QC data management solutions, which include our comprehensive Unity Interlaboratory Program that helps to ensure the reliability and precision of test systems."

Additionally, the two companies have also signed an agreement whereby Bio-Rad will support new Siemens assays through the addition of new analytes or new control products to Bio-Rad’s high quality line of independent third-party controls. Siemens has a comprehensive assay pipeline that will now have consistent control materials for optimal reliability of test results.

This partnership reflects Siemens’ efforts to expand its regional footprint, which is a goal of the recently launched Siemens Agenda 2013 program. Agenda 2013 is a two-year global initiative to further strengthen the Healthcare Sector's innovative power and competitiveness. Specific measures will be implemented in four fields of action: Innovation, Competitiveness, Regional Footprint, and People Development.

 

(來源: Siemens )


全年征稿 / 資訊合作

聯系郵箱:[email protected]

版權與免責聲明

  • 凡本網注明“來源:來寶網”的所有作品,版權均屬于來寶網,轉載請必須注明來寶網, http://www.vhyrck.live,違反者本網將追究相關法律責任。
  • 本網轉載并注明自其它來源的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點或證實其內容的真實性,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品來源,并自負版權等法律責任。
  • 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。


35选7开奖查询